[go: up one dir, main page]

NO20080594L - Heteroaryl-substituerte diazatricykloalkaner, fremgangsmater for fremstilling og anvendelse derav - Google Patents

Heteroaryl-substituerte diazatricykloalkaner, fremgangsmater for fremstilling og anvendelse derav

Info

Publication number
NO20080594L
NO20080594L NO20080594A NO20080594A NO20080594L NO 20080594 L NO20080594 L NO 20080594L NO 20080594 A NO20080594 A NO 20080594A NO 20080594 A NO20080594 A NO 20080594A NO 20080594 L NO20080594 L NO 20080594L
Authority
NO
Norway
Prior art keywords
compounds
methods
substituted
nachr
activity
Prior art date
Application number
NO20080594A
Other languages
English (en)
Inventor
Anatoly A Mazurov
Lan Miao
Jozef Klucik
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO20080594L publication Critical patent/NO20080594L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

Foreliggende oppfinnelse angår amid- og urinstoff-derivater av heteroaryl-substituerte diazatricykloalkaner med formel (I) med definisjonene angitt i beskrivelsen, farmasøytiske preparater omfattende forbindelsene, metoder for fremstilling av forbindelsene og metoder for behandling ved anvendelse av forbindelsene. Mer spesifikt involverer metodene for behandling modulering av aktiviteten til a7 nAChR undertype ved administrering av én eller flere av forbindelsene for å behandle eller forhindre lidelser mediert av a7 nAChR undertype. Diazatricykloalkaner består typisk av et 1-azabicyklooktan kondensert til en pyrrolidin-ring. Substituent heteroarylgrupper er 5- eller 6-leddede heteroaromatiske ringgrupper, så som 3-pyridinyl- og 5-pyrimidinylgrupper, som er tilknyttet direkte til diazatricykloalkanet. Det sekundære nitrogen i pyrrolidingruppen er substituert med en arylkarbonyl- (amidtype derivat) eller arylaminokarbonyl- (N-arylkarbamoyl) (urinstoff-type derivat) gruppe. Forbindelsene er fordelaktige for terapeutiske anvendelser som krever selektiv interaksjon ved visse nAChR undertyper. Dvs. forbindelsene modulerer aktiviteten til visse nAChR undertyper, spesielt a7 nAChR undertype og har ikke merkbar aktivitet mot muskarine reseptorer. Radioaktivt merkede versjoner av forbindelsene kan anvendes for diagnostiske metoder. (I)
NO20080594A 2005-08-22 2008-02-01 Heteroaryl-substituerte diazatricykloalkaner, fremgangsmater for fremstilling og anvendelse derav NO20080594L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71013005P 2005-08-22 2005-08-22
PCT/US2006/032685 WO2007024814A1 (en) 2005-08-22 2006-08-21 HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
NO20080594L true NO20080594L (no) 2008-05-16

Family

ID=37508012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080594A NO20080594L (no) 2005-08-22 2008-02-01 Heteroaryl-substituerte diazatricykloalkaner, fremgangsmater for fremstilling og anvendelse derav

Country Status (17)

Country Link
US (2) US7732607B2 (no)
EP (1) EP1917265B1 (no)
JP (1) JP2009506037A (no)
KR (1) KR20080035649A (no)
CN (1) CN101248073A (no)
AT (1) ATE482959T1 (no)
AU (1) AU2006283453A1 (no)
BR (1) BRPI0614874A2 (no)
CA (1) CA2618700A1 (no)
DE (1) DE602006017235D1 (no)
EA (1) EA014738B1 (no)
IL (1) IL189204A0 (no)
MX (1) MX2008002467A (no)
NO (1) NO20080594L (no)
NZ (1) NZ565628A (no)
WO (1) WO2007024814A1 (no)
ZA (1) ZA200801242B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20100179186A1 (en) * 2008-10-10 2010-07-15 University Of Kentucky Research Foundation USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
JP5657556B2 (ja) * 2008-11-11 2015-01-21 ターガセプト，インコーポレイテッド α７選択的リガンドを用いる治療
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2015191401A1 (en) * 2014-06-13 2015-12-17 Bristol-Myers Squibb Company Tricyclic compounds as alpha- 7 nicotinic acetylcholine receptor ligands
AU2016239861A1 (en) * 2015-04-03 2017-10-12 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
DK3344628T5 (da) 2015-09-04 2021-07-26 Janssen Pharmaceutica Nv Terapeutiske forbindelser og syntese
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
JP2553020B2 (ja) * 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
US5273972A (en) * 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
PT1027336E (pt) 1997-10-27 2005-01-31 Neurosearch As Heteroarildiazacicloalcanos como ligandos colinergicos de receptores nocotinicos de acetilcolina
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos

Also Published As

Publication number Publication date
HK1115594A1 (en) 2008-12-05
US20100197720A1 (en) 2010-08-05
WO2007024814A1 (en) 2007-03-01
IL189204A0 (en) 2009-08-03
CN101248073A (zh) 2008-08-20
BRPI0614874A2 (pt) 2011-04-19
US20070197579A1 (en) 2007-08-23
ZA200801242B (en) 2009-02-25
US7732607B2 (en) 2010-06-08
EA200800656A1 (ru) 2008-08-29
DE602006017235D1 (de) 2010-11-11
EA014738B1 (ru) 2011-02-28
KR20080035649A (ko) 2008-04-23
NZ565628A (en) 2011-03-31
CA2618700A1 (en) 2007-03-01
AU2006283453A1 (en) 2007-03-01
EP1917265A1 (en) 2008-05-07
ATE482959T1 (de) 2010-10-15
JP2009506037A (ja) 2009-02-12
EP1917265B1 (en) 2010-09-29
MX2008002467A (es) 2008-04-07

Similar Documents

Publication Publication Date Title
NO20080594L (no) Heteroaryl-substituerte diazatricykloalkaner, fremgangsmater for fremstilling og anvendelse derav
EA200971143A1 (ru) Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MX2010009922A (es) Activadores de piridazinona glucocinasa.
ZA202408030B (en) Tricyclic heterocyclic derivatives, compositions and uses thereof
NO20084852L (no) MGLUR5 modulatorer V
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2009008323A (es) Derivados heterociclicos como receptores muscarinicos m3.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MXPA05010020A (es) Derivados de oxamida.
MX2025012818A (es) Derivados de heterociclicos triciclicos, composiciones y usos de estos
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application